Some patients may have temporary memory loss after the procedure because of monitored anesthesia care
water for injection (WFI), sterile water solution, or bacteriostatic water for injection (BWFI) may be used
Lancet 330(8571):13001304 [Google Scholar] Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
In line with clinical data, GLP-1R agonism may also directly influence food preference through modulation of taste receptor expression
Written by Ali Rza Akn Microbiome Scientist, Author & Founder of Next-Microbiome Ali Rza Akn is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation
Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA
